Page last updated: 2024-11-07

icig 1163

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ICIG 1163: RN given refers to parent cpd; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100268
CHEMBL ID455703
MeSH IDM0080766

Synonyms (11)

Synonym
rpcnu
(cloro-2-etil)-1-(ribopiranosiltriacetato-2',3',4')-3-nitrosourea [italian]
nsc 279193
1-(2-chloroethyl)-1-nitroso-3-ribopyranosylurea 2',3',4'-triacetate
(chloro-2-ethyl)-1-(ribopyranosyltriacetate-2',3',4')-3-nitrosourea
icig 1163
n-(2-chloroethyl)-n-nitroso-n'-(2,3,4-tri-o-acetyl-d-ribopyranosyl)urea
i.c.i.g. 1163
urea, 1-(2-chloroethyl)-1-nitroso-3-ribopyranosyl-, 2',3',4-triacetate
CHEMBL455703
(cloro-2-etil)-1-(ribopiranosiltriacetato-2',3',4')-3-nitrosourea
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (87.50)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]